Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 2Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Melanoma 11Leukemia, Myeloid, Acute 5Uveal Melanoma 4Prostatic Neoplasms 4Myelodysplastic Syndromes 4Uterine Cervical Neoplasms 3Sarcoma 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Gastrointestinal Stromal Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Gliosarcoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cyclophosphamide 32Tacrolimus 29fludarabine 27Mycophenolic Acid 23fludarabine phosphate 22Busulfan 19Whole-Body Irradiation 18Melphalan 16Methotrexate 15Antilymphocyte Serum 14Rituximab 12Bortezomib 11Stem Cell Transplantation 10Cyclosporine 10thymoglobulin 9Sirolimus 9Granulocyte Colony-Stimulating Factor 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Interviews as Topic 7Filgrastim 7Dexamethasone 7Clofarabine 7Blood Specimen Collection 6Alemtuzumab 6merphos 5Voriconazole 5Standard of Care 5Nivolumab 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hematologic Neoplasms × CTLA-4 Antigen × Clear all
NCT01919619 2024-12-03

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 2 Completed
41 enrolled 11 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

National Cancer Institute (NCI)

Phase 1 Completed
71 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡